Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

M04NM11

Next Previous
Drug Profile

M04NM11

Alternative Names: Hepatitis B Candidate 1; Hepatitis B Virus immunobiotic - Emergent Biosolutions; Live attenuated Salmonella enterica serovar Typhi (Ty2 aroC- ssaV- ssaG-HBcAg) RSC5; M04NM11 hepatitis B immunotherapy

Latest Information Update: 09 Aug 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emergent BioSolutions
  • Developer Emergent Product Development UK
  • Class Antivirals; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 08 Aug 2019 Discontinued - Phase-II for Hepatitis B in United Kingdom, Serbia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top